Your Directors are pleased to present the Sixty-Seventh Annual Report on the business operations of the Company together with the Audited Accounts for the financial year ended 31st March, 2014 and on the state of affairs of the Company.
The highlights of the performance of the Company for the year ended 31st March, 2014 is summarized below:
|Particulars||Financial Year ended||Financial Year ended|
|31st March, 2014||31st March, 2013|
|Revenue from Operations (Gross)||74045||64163|
|Less: Excise Duty||(1274)||(1124)|
|Revenue from Operations (Net)||72771||63039|
|Add: Other Income||175||150|
|Profit Before Finance Cost, Depreciation & Tax||12182||9396|
|Less: Finance Cost||1880||2187|
|Less: Depreciation & Amortisation||3091||2372|
|Profit Before Tax||7211||4837|
|Less: Provision for Taxation|
|- Earlier Years Adjustment||338||28|
|- MAT Credit Entitlement||(968)|
|Net Profit After Tax||5790||4266|
|Balance brought forward||13412||11832|
|Amount available for appropriation||19202||16098|
|Transfer to General Reserve||1500||1500|
|Balance carried forward||16193||13412|
Results from Operations:
The FY 2013-14 under consideration witnessed a continued slowdown in the Indian economy. Delays in project clearances and difficulties in achieving the financial closure affected the industry resulting in sluggish growth. Added to this was higher inflation and adverse climatic conditions resulting in slowdown in agriculture. The cumulative impact was lower industrial production and slower growth in GDP. In the pharmaceutical industry in particular there was confusion because of lack of clarity due to introduction of NPPA for NLEM Products which resulted in less than expected performance for many companies. Internationally also the Indian pharmaceutical companies faced a lot of challenges from regulatory authorities in various countries resulting in the lower growth of business. However, we were proactive to take effective steps to overcome these difficulties as a result of which our overall performance was not affected to a large extent.
During the year 2013-14, the total income of the Company amounted to Rs.72946 lakhs as compared to Rs.63189 lakhs in the previous year. This represents a 15.44% growth. The Profit before Tax (PBT) at Rs.7211 lakhs as compared to Rs.4837 lakhs in the previous year representing a 49.08% growth. After providing for Income Tax and MAT, the Net Profit After Tax (PAT) amounts to Rs.5790 lakhs as against Rs.4266 lakhs in the previous year. The increase in PBT & PAT is mainly due to reduction in input and other costs.
A detailed discussion on the business performance and future outlook is included in Management Discussion & Analysis which forms part of the Directors' Report.
Dividend & Reserves:
Your Directors are pleased to recommend a dividend of Rs.1.40 per share on the face value of Rs.2/- each (70%). The dividend payout will aggregate Rs.1290.10 lakhs (Previous year: Rs.1013.65 lakhs) and the tax on distributed profits payable by the Company would amount to Rs.219.25 lakhs (Previous year Rs.172.27 lakhs). The Directors have recommended transfer of an amount of Rs.1500 lakhs to General Reserves (Previous year Rs.1500 lakhs).
Company's working capital facilities are rated A1+ and long term borrowings are rated A+ by ICRA. A1+ rating indicates highest credit quality rating and A+ rating indicates adequate credit quality rating.
Indoco's Corporate Social responsibilities continue to be focused on promoting education, health and hygiene. In this connection the Company during the year under consideration made donations of Rs.45.51 lakhs. In addition to the above, the Company during the year made substantial donation of free medicines to charitable bodies for distribution among the needy.
The Company has two subsidiary companies:
1. Xtend Industrial Designers and Engineers Pvt. Limited (Formerly known as Indoco Industrial Designers and Engineers Pvt. Limited)
2. Indoco Pharmchem Limited.
In accordance with the general exemption granted by the Ministry of Corporate Affairs, Government of India, the Balance Sheet, Profit and Loss Account and other documents of the subsidiary companies are not being attached with the Balance Sheet of the Company. However the financial information of the subsidiary companies is disclosed in the Annual Report in compliance with the said circular. The Company will make available the Annual Accounts of the subsidiary companies and the related detailed information to any members of the Company who may be interested in obtaining the same. The Annual Report of the subsidiary companies will also be kept open for inspection at the Registered Office of the Company and that of the respective subsidiary companies. The Consolidated Financial Statement of your Company includes the financial results of its subsidiary companies.
Consolidated Financial Statements :
In accordance with Accounting Standard AS-21, the Audited Consolidated Financial Statements are provided in the Annual Report.
In compliance with the provisions of Clause 49 of the Listing Agreement, the Report on the Corporate Governance is annexed and forms part of the Annual Report. The Report is duly certified by the Statutory Auditors of the Company whose certificate is also annexed.
Directors' Responsibility Statement
To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors make the following statement in terms of Section 217 (2AA) of the Companies Act, 1956:
i. That in the preparation of annual accounts, the applicable accounting standards have been followed and no material departures have been made from the same;
ii. That they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profits of the Company for that year;
iii. That proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
iv. That the annual accounts have been prepared on a 'going concern' basis.
The Company at its Board Meeting held on 28th May, 2014, appointed Dr. Anand Nadkarni as Non Executive Director of the Company liable to retire by rotation. Dr. Anand Nadkarni is a Consultant Psychiatrist and a Corporate Trainer and Human Resource Consultant for a number of major corporate organizations. The Board considers that the appointment of Dr. Anand Nadkarni would be of immense benefit to the Company. Dr. Anand Nadkarni holds office up to the date of the ensuing Annual General Meeting. The Company has received requisite notice in writing from a member proposing Dr. Anand Nadkarni for appointment as a Non Executive Director.
Your Directors have proposed to alter the terms of appointment of Ms. Aditi Panandikar, Managing Director and Mr. Sundeep V. Bambolkar, Jt. Managing Director so as to make them Directors retiring by rotation for reasons as stated in the Explanatory Statement to the Notice of 67th Annual General Meeting of the Company (forming part of this Annual Report) pursuant to Section 102 of the Companies Act, 2013.
It has been proposed to make the composition of the Board in line with Section 152 of the Companies Act, 2013 on account of provisions of Section 152(6) of the Companies Act, 2013. Accordingly Independent Directors are being reappointed for a period of 5 years from the date of the AGM and they will not be liable to retire by rotation.
The profile of directors seeking reappointment pursuant to Clause 49(IV)(G)(i) of the Listing Agreement with the Stock Exchanges is therefore included in the annual report.
M/s. Patkar & Pendse, Chartered Accountants, hold office as Auditors till the conclusion of the ensuing Annual General Meeting, and are eligible for re-appointment. M/s. Patkar & Pendse have confirmed their eligibility as required by Section 224 (1B) of the Companies Act, 1956 read with Section 139 of the Companies Act, 2013 to act as Auditors of the Company. They have also conveyed their willingness to accept the office as Auditors, if re-appointed. The Audit Committee of the Board has recommended their re-appointment for a period of 3 years from the conclusion of the forthcoming Annual General Meeting till the conclusion of the Seventieth Annual General Meeting.
In terms of the Order issued by the Central Government under Section 233B of the Companies Act, 1956, the Company was required to appoint cost auditors to get the audit of the cost records of the Company done by a member of the Institute of Cost & Works Accountants of India (ICAI). Accordingly for FY 2012-2013, the Company had appointed M/s. Sevekari, Khare & Associates of the ICAI as the Cost auditor to get the audit of the cost records done. For the Financial year 2012-13 M/s. Sevekari, Khare & Associates was required to submit their report by 27th September, 2013 and they have submitted the report on 6th September, 2013. For the financial year 2013-14, M/s Sevekari, Khare & Associates would be required to submit the reports by 27th September, 2014.
For the financial year 2014-15, M/s Sevekari, Khare & Associates has been appointed the Cost auditor by the Company. They would be required to submit the reports by 27th September, 2015.
Information in Terms of Section 217 (1)(e) & Section 217 (2A)
Information in terms of the provision of Section 217(1)(e) of the Companies Act, 1956, read with Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988, as amended, is contained in Annexure-I to this report and forms part of the Report.
Information in terms of the provision of Section 217 (2A) of the Companies Act, 1956, read with Companies (Particulars of Employees) Rules, 1975 as amended, is contained in Annexure-II to this report. However, in terms of the provisions of Section 219(1)(b) of the Companies Act, 1956, the said annexure has not been forwarded to the members and those members interested in the said information may write to the Company Secretary at the registered office of the Company.
The employees' relation at all levels and at all units continued to be cordial during the year.
Your Directors wish to place on record their appreciation of the dedicated efforts by employees at all levels. The Directors also wish to place on record their word of sincere appreciation to the bankers & financial institutions, the investors, the vendors, the customers, the medical profession and all other business associates for their continued support.
For and on behalf of the Board of Directors
SURESH G. KARE
Date: 28th May, 2014.
To The Directors' Report
Particulars required under Section 217(1)(e) of the Companies Act, 1956 read with the Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988.
A. CONSERVATION OF ENERGY
(a) Details of Energy Conservation measures taken in 2013-14
1. Replacement of Reciprocating and Vapour absorption chiller to Screw chiller to save electricity and maintenance cost.
2. Human motion sensors installed for air conditions and lamps for various locations to save electricity.
3. Installation of LED lamps in various departments to save electricity.
4. Installation of sophisticated Demineralised plant to reduce chemical cost and conservation of water.
5. Installation of additional Screw air compressors.
6. Condensate water recovery of process steam and utilizing it as a feed water for boiler.
(b) Additional Investments and proposals, if any, being implemented for reduction of consumption of energy
1. Feasibility of gas as a fuel for boiler to reduce stack emission and cost benefit.
2. Installation of solar system to generate electricity for plant lighting purpose.
3. Rain harvesting to save rain water.
4. Replacement of pending reciprocating air compressor to Screw air compressor.
(c) Impact of measures at (a) & (b) above for reduction of energy consumption & consequent on the cost of production of good
1. Reduction in Energy cost.
2. Reduced Fuel and water consumption.
3. Improved air compressor efficiency.
4. Reduction of air pollution
(d) Total energy consumption and energy consumption per unit of production:
1. Power and Fuel Consumption
|Particulars||Current Year||Previous Year|
|a) Purchased Units (in lakhs)||239.30||222.52|
|Total Amount (Rs. lakhs)||1338.74||1224.49|
|b) Own generation|
|i) Through diesel generator|
|Units per ltr. of diesel oil (KWH)||2.84||3.05|
|ii) Through steam turbine/generator|
|Units per ltr of fuel oil/gas|
|3) Furnace Oil|
|Qty (Kilo litres)||410.87||322.41|
|Total Amount (Rs.lakhs)||219.98||146.88|
|Average rate (Rs.)||53.54||45.56|
|4) Others/internal generation (briquettes, cashew seeds etc.)|
|Total Cost (Rs.lakhs)||158.08||151.14|
2. Consumption per unit of production
On account of the manufacture of products with varied pack size/units of measures, it is not practicable to express the consumption of power per unit of production.
B. TECHNOLOGY ABSORPTION
Efforts made in technology absorption:
Research and Development (R&D)
1. Specific areas in which Research and Development are carried out by the Company are:
Development of Complex Ophthalmic Formulations like Nanosuspensions, Ophthalmic Gels, High viscosity combination products are in progress. Ophthalmic ointments and emulsions and First-To-File projects are also in the pipeline of development projects.
2. Benefits derived as a result of above efforts are
Creation of the Company's own intellectual property which can be exploited commercially and for preventing competitors from blocking ideas for design around manufacturing processes. R&D efforts give an edge over the competitors in the market place in terms of early entry and better pricing. The Company's patent portfolio consists of 4 granted formulation patents and 20 patent application applied for
3. Future plan of action
The Company intends to file multiple Para IV applications by using non-infringing strategies for different dosage forms and thereby patenting innovating ideas to create our own intellectual property. The Company has
- Filed multiple patent applications in India and two PCT applications and plans to enter Europe and USA for the same.
- Has 3-4 Para IV applications in pipeline and also has plans to file with our partners in the USA, FTF Para IV applications for ophthalmic products.
- Has started scrutinizing different patented and off-patented potential molecules for 505(b)(2) applications for the USA market.
- Has plans to launch in the coming years multiple molecules in Europe 4. Expenditure on R & D:
|Particulars||Current Year||Previous Year|
|4 Total R&D expenditure as a % of total net sales||2.41||2.74|
Technology absorption, adaptation and innovation
1. Efforts, in brief, made towards technology absorption, adaptation and innovation and benefits derived as a result of such efforts During the year the following processes were successfully implemented: a) Domperidone base and maleate: The Technology for synthesizing this molecule was developed in-house and successfully implemented at plant level.
b) Betaxolol Hydrochloride-The process for manufacturing of Betaxolol Hydrochloride was improved at R&D and scaled up at plant level with better yield and quality. c) Fabuxostat: The technology was developed inhouse at our R&D. The product is under commercialization. d) Olopatadine HCl, bromfenac Sodium and Brimonidine Tartrate: The batch size for these API's was scaled from existing 2 kgs to 20 kgs for Olopatadine HCl, 1 kg to 2 kg for Bromfenac Sodium and 0.8 kg to 5 kg for Brimonidine Tartrate to cater the increased market demands.
2. In case of imported technology (imported during the last 5 years reckoned from the beginning of the financial year), following information may be furnished:
|a) Technology Imported||- None|
|b) Year of import||- N.A.|
|c) Has technology been fully absorbed||- N.A.|
|d) If not fully absorbed, areas where this has not taken place, reasons thereof and future plans of action||- N.A.|
C. FOREIGN EXCHANGE EARNINGS AND OUTGO
(a) Activities relating to exports; initiatives taken to increase exports; development of new export markets for products and services; and export plans: The Company participates in International Conferences and exhibitions in US, Europe, Japan and other countries. Such participation helps us in expanding our network of customers. During the year the Company continued with its efforts of filing own Dossiers in Europe through DCP (Decentralization Procedure) route and filing own ANDA's with USFDA. The product basket has been expanded and scope of services offered is also extended to analytical and synthesis of impurities, reference standards and building blocks of NCEs for MNCs. The Company plans to move up in the value chain by offering new products/services and expanding into newer territories is well on track.
(b) Total foreign exchange used and earned
|Particulars||Current Year||Previous Year|
|1 Total foreign exchange earned (CIF)||25434.60||21871.04|
|2 Total foreign exchange used||5490.76||4303.24|
For and on behalf of the Board of Directors
SURESH G. KARE
Date: 28th May, 2014.
|30-Jul-15||Indoco Remedies Q1 net profit at Rs. 20.3 crore|
|27-May-15||Indoco Remedies net profit at Rs. 18.7 crores|
|01-Apr-15||Indoco Remedies acquires Piramals Clinical Research Division|
|01-Apr-15||Entering high growth phase|
|05-Mar-15||56 stocks hit 52-week high on BSE today|
Suresh G Kare , Chairman
D M Gavaskar , Director
Sundeep V Bambolkar , Joint Managing Director
Aditi Kare Panandikar , Managing Director
Company Head Office / Quarters:
Indoco House 166 C S T Road,
Phone : Maharashtra-91-022-26541851-55 / Maharashtra-
Fax : Maharashtra-91-022-26523067/66936241 / Maharashtra-
E-mail : email@example.com
Web : http://www.indoco.com
|Scheme Name||No. of Shares|
|DSP BR Micro-Cap Fund (G)||29,13,658|
|UTI-Mid Cap Fund (G)||16,38,323|
|Reliance Pharma Fund (G)||10,84,077|
|SBI Magnum Midcap Fund (G)||6,98,057|
|SBI Tax Advantage Fund - Series I (G)||6,78,105|